This should be trading much closer to book value. Pipeline seems overvalued. The share price should better reflect the risky and long-term nature of drug development.
Expect it to settle around the $1 mark, and then trade sideways from there. The Evogenix merger will probably cut 20 to 30% off the combined entity, as I believe the premium paid was excessive.
- Forums
- ASX - By Stock
- PTD
- heading lower
PTD
unknown
heading lower
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
DVP
Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place
NEWS
Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo
BOE
Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan
NEWS
Is oil undervalued?